Zacks Research increased their FY2024 EPS estimates for shares of Sanofi in a report issued on Wednesday, November 13th.

Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity M ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

The current US Supreme Court has no fundamental understanding of a range of medical, engineering, technological, or ...

Brad Lightcap, COO, OpenAI "We believe AI can accelerate drug development, bringing new treatments to patients more quickly. This first product from our collaboration with Sanofi and Formation Bio is ...

Deal-making has slowed in recent years, largely due to high interest rates, soaring company valuations and a tight regulatory ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical development.

Powered by PandaOmics, Insilico’s proprietary generative biology AI platform, the joint R&D team comprising Insilico Medicine and Sanofi colleagues focused on highly novel targets known to be ...

French pharma giant Sanofi is selling off its consumer healthcare business Opella. US-based investment firm Clayton, Dubilier & Rice (CD&R) is to take a controlling 50% stake, while Sanofi will retain ...